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Most notable among the acute phase proteins is serum amyloid A (SAA), levels of which
can increase 1000-fold during infections, aseptic inflammation, and/or trauma. Chronically
elevated SAA levels are associated with a wide variety of pathological conditions, includ-
ing obesity and rheumatic diseases. Using a recombinant hybrid of the two human SAA
isoforms (SAA1 and 2) that does not exist in vivo, numerous in vitro studies have given
rise to the notion that acute phase SAA is a pro-inflammatory molecule with cytokine-like
properties. It is however unclear whether endogenous acute phase SAA per se medi-
ates pro-inflammatory effects. We tested this in samples from patients with inflammatory
arthritis and in a transgenic mouse model that expresses human SAA1. Endogenous human
SAA did not drive production of pro-inflammatory IL-8/KC in either of these settings. Human
neutrophils derived from arthritis patients displayed no signs of activation, despite being
exposed to severely elevated SAA levels in circulation, and SAA-rich sera also failed to acti-
vate cells in vitro. In contrast, two recombinant SAA variants (the hybrid SAA and SAA1) both
activated human neutrophils, inducing L-selectin shedding, production of reactive oxygen
species, and production of IL-8. The hybrid SAA was approximately 100-fold more potent
than recombinant SAA1. Recombinant hybrid SAA and SAA1 activated neutrophils through
different receptors, with recombinant SAA1 being a ligand for formyl peptide receptor 2
(FPR2).We conclude that even though recombinant SAAs can be valuable tools for studying
neutrophil activation, they do not reflect the nature of the endogenous protein.
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INTRODUCTION
Serum amyloid A (SAA) is one of the most prominent acute phase
proteins in the body and the levels in plasma can rise 1000-fold
in response to inflammation, infection, or tissue injury. The SAAs
comprise a family of apolipoproteins with characteristic structural
features (Uhlar and Whitehead, 1999). In humans, four distinct
SAA genes exist, SAA1-SAA4. The SAA3 is not expressed at all
(Sellar et al., 1994) while SAA4 is constitutively expressed. The
remaining two isoforms, SAA1 and SAA2, are the acute phase vari-
ants of SAA and are mainly produced by hepatocytes (Uhlar and
Whitehead, 1999), although extrahepatic SAA production can also
occur (Upragarin et al., 2005). In obesity, a condition character-
ized by low-grade inflammation with moderately elevated levels
of acute phase proteins (Smorlesi et al., 2012), adipose tissue is
the major source of SAA (Sjoholm et al., 2005). Acute phase SAA
is the precursor of reactive amyloidosis which can follow after
long-standing inflammatory conditions, e.g., rheumatic diseases.
During reactive amyloidosis, deposits of amyloid A form amyloid
fibrils in tissue, leading to progressive organ failure (Benson et al.,
2006). In line with this, SAA has been shown to serve as a reliable
biomarker for the assessment of inflammatory joint disease and
it has been suggested that SAA is directly involved in the patho-
genesis of inflammatory arthritis (Cunnane et al., 2000; Connolly
et al., 2012).
As for the function of acute phase SAA in the context of
immunology, the endogenous protein has been elegantly shown
to serve as an innate recognition molecule that opsonizes Gram-
negative bacteria by binding to Outer membrane protein A (Shah
et al., 2006). Based on in vitro studies employing a recombinant
protein (described below), SAA is also believed to possess a variety
of directly pro-inflammatory properties with cytokine-like fea-
tures; most notably it has been described as a chemoattractant for
phagocytic cells and to induce production of pro-inflammatory
cytokines such as IL-8 (Badolato et al., 2000; Furlaneto and Campa,
2000; Hatanaka et al., 2004; Bjorkman et al., 2008; He et al.,
2008; Lee et al., 2008). In line with this, a recent paper describes
the existence of activated neutrophils in circulation of melanoma
patients (De Santo et al., 2010) where the authors conclude that
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high levels of endogenous plasma SAA are responsible for the cell
activation.
The pro-inflammatory effects of SAA have mainly been dis-
sected by the use of a commercially available recombinant form
of SAA (Badolato et al., 2000; He et al., 2003, 2008; Bjorkman
et al., 2008; Lee et al., 2008). This recombinant SAA hybrid
(rSAAh) is a chimeric molecule corresponding to the sequence of
human SAA1 with an additional N-terminal methionine and two
mutated amino acids corresponding to the sequence of SAA2. In
terms of receptor preference for mediating its pro-inflammatory
effects, rSAAh has been reported to be a ligand of a variety
of receptors, including Toll-like receptor 2 (Cheng et al., 2008)
and the scavenger receptors CLA-1 (Baranova et al., 2005) and
CD36 (Baranova et al., 2010). In addition, the chemoattractant
receptor formyl peptide receptor 2 (FPR2; formerly FPRL1) has
been shown to be the preferred receptor for many SAA-induced
effects on phagocytes (Su et al., 1999; He et al., 2003; Lee et al.,
2008).
The design of the rSAAh is based on genetic variation within
the SAA1 and SAA2 genes. Each of the individual substitutions of
rSAAh has been described as naturally occurring variants of SAA1
(Baba et al., 1992). An allelic variant identical to the full sequence
of rSAAh has however to our knowledge not been described. Thus,
the rSAAh protein is not identical to any of the reported human
SAA isoforms and we have previously demonstrated that this
recombinant protein is functionally different from the endogenous
acute phase SAA present in circulation during severe inflamma-
tion. Using purified endogenous acute phase SAA, as well as blood
samples from rheumatic patients with elevated levels of endoge-
nous SAA, we found the endogenous SAA to be remarkably inert,
whereas rSAAh potently activated human phagocytes (Bjorkman
et al., 2010). Despite these discrepancies with regards to sequence
and function, rSAAh continues to be used as a substitute for the
native molecule.
Recently, a recombinant SAA1 (rSAA1) was launched with an
amino acid sequence identical to the endogenous human SAA1.
This inspired us to further investigate the role of SAA1 in inflam-
matory events, and to discern whether this molecule can better
represent the endogenous protein than the rSAAh. We first found
equal plasma levels of IL-8 between healthy controls and patients
with severely elevated SAA levels due to inflammatory arthritis,
indicating that native acute phase SAA does not drive the pro-
duction of this pro-inflammatory cytokine. We also employed a
transgenic mouse model with circulating levels of SAA similar to
the levels seen in human obesity (Olsson et al., 2011). Also in
this setting, we found that plasma levels of murine IL-8 (KC),
were not higher in transgenic than in wild type (WT) mice. Both
recombinant forms of SAA activated pro-inflammatory mecha-
nisms in human neutrophils, in striking contrast to the effects
induced by SAA-rich patient plasma, which failed to activate neu-
trophils in vitro as well as in vivo. The rSAA1-induced effects
were mediated by FPR2, whereas this receptor did not medi-
ate neutrophil responses to rSAAh. We conclude that although
the recombinant SAA proteins can be useful tools for studies of
neutrophil activation, they are invalid substitutes for endogenous
acute phase SAA.
PATIENTS AND METHODS
REAGENTS
HRP was purchased from Boehringer-Mannheim (Mannheim,
Germany) and LPS from Escherichia coli (serotype O111:B4),
Isoluminol, and TNF were from Sigma Chemical Co. (St. Louis,
MO, USA). Dextran and Ficoll-Paque were from Pharmacia (Upp-
sala, Sweden). The FPR2 antagonist WRWWWW (WRW4) was
from GenScript Corp. (Piscataway, NJ, USA) and acetoxymethy-
lated Fura-2 (Fura-2AM) from Molecular Probes Inc. (Eugene,
OR, USA). Anti-CD62L (L-selectin) was from BD Biosciences
(Stockholm, Sweden). Cyclosporin H was provided by Novartis
Pharma (Basel, Switzerland). Annexin V FLUOS was from Roche
Diagnostics (Mannheim, Germany) and 7-amino-actinomycin D
(7-AAD) from BD Biosciences (Stockholm, Sweden).
The recombinant SAA proteins were from PeproTech Inc.
(Rocky Hill, NJ, USA) and had both endotoxin levels <0.1 ng/µg
(1 EU/µg). Recombinant Human Apo-SAA (with amino acid
sequence, cat. no 300-13; referred to in the text as rSAAh), is a
hybrid molecule between sequences for SAA1 and SAA2 (two sub-
stitutions are derived from the sequence of SAA2: asparagine for
aspartic acid at position 60 and arginine for histidine at position
71). The sequence for recombinant Human Apo-SAA1, cat. no
300-53; referred to in the text as rSAA1) is solely based on the
sequence for SAA1. Both recombinant proteins reportedly con-
tain an N-terminal methionine residue not present in the human
SAA sequences (Figure 1).
PATIENTS
Peripheral blood was obtained from patients in flares of various
forms of inflammatory arthritis (Table 1). All patients gave written
informed consent. The study was approved by the Regional Ethics
Board (No S010-03).
TRANSGENIC MOUSE MODEL WITH ADIPOSE TISSUE EXPRESSION OF
HUMAN SAA1
Generation of a transgenic mouse model with over-expression of
human SAA1 in the adipose tissue has previously been described
(Olsson et al., 2011). Levels of human SAA were measured in
plasma from the hSAA transgenic animals and four WT animals
using the Human SAA ELISA kit (Biosource, Camarillo, CA, USA).
Undiluted plasma from WT or transgene mice were subjected to
a mouse CXCL1/KC DuoSet ELISA development kit (R&D Sys-
tems, Minneapolis, MN, USA) according to the manufacturer’s
description.
All animal study protocols were approved by the local Ethics
Committee for animal studies at the administrative court of
Appeals in Gothenburg, Sweden, approval numbers 201-2006 and
281-2008.
ISOLATION OF HUMAN NEUTROPHILS AND PREPARATION OF PLASMA
Blood was collected in heparinized tubes and neutrophils were
either analyzed directly after lysis of erythrocytes concomi-
tant with fixation by lysis buffer (BD Biosciences, Sweden)
or after purification according to Boyum et al. (1991) Neu-
trophils from buffy coats were isolated by Ficoll-Pacque gra-
dient centrifugation. Purified neutrophils were resuspended in
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FIGURE 1 | Amino acid sequences of endogenous SAA1, rSAA1,
and rSAAh. The rSAAh is a hybrid molecule corresponding mainly to
human SAA1 with the exception of the presence of an N-terminal
methionine and two substitutions (derived from the sequence of
SAA2): asparagine for aspartic acid at position 60 and arginine for
histidine at position 71 (marked by asterisks). Recombinant SAA1 is
identical to endogenous SAA1 except for the presence of an N-terminal
methionine.
Table 1 | Patients included in the study.
Patient
no.
SAA in plasma
µM (mg/l)
Diagnosisa Treatmentb Gender
1 15 (180) RA MTX Female
2 73 (855) RA SZS, pred. Male
3 49 (570) SpA/Am pred. Male
4 3 (32) RA MTX, pred. Male
5 78 (910) PsA pred. Male
6 428 (5000) RA MTX, pred.
SZS, NSAIDs
Female
7 368 (4300) Wg methpred. Male
8 12 (140) SpA MTX, α-TNF Male
9 197 (2300) RA MTX,
NSAIDs
Male
aRA, rheumatoid arthritis; SpA/Am, spondyloarthritis/Amyloidosis; PsA, psoriasis
arthritis; Wg, Wegeners granulomatosis.
bMTX, Methotrexate; pred., prednisolone; SZS, Sulfasalazine; NSAIDs, non-
steroidal anti-inflammatory drugs; methpred., methylprednisolone.
Krebs-Ringer phosphate buffer containing glucose (KRG) sup-
plemented with 1 mM Ca2+ and stored on melting ice until
use. Blood samples obtained for preparation of plasma was
centrifuged for 10 min at 400× g in room temperature, after
which plasma was removed and stored at −70˚C. Plasma from
patients and controls were analyzed for SAA content using a
hSAA ELISA Kit from Invitrogen (Camarillo, CA, USA; upper
detection limit 600 mg/l and lower limit 11 mg/l) by the Clini-
cal Immunological Laboratory (Sahlgrenska University Hospital).
Plasma SAA of <11 mg/l, corresponding to 1µM, are considered
normal.
NADPH-OXIDASE ACTIVITY AND PRIMING
Neutrophil NADPH-oxidase activity was determined using an
isoluminol-enhanced chemiluminescence technique, which mea-
sures the release of superoxide anion, the primary oxygen metabo-
lite generated by the assembled NADPH-oxidase (Segal et al.,
2012). The chemiluminescence activity was measured as described
in Dahlgren et al. (2007). Where indicated, neutrophils were
incubated at 37˚C for 20 min in the presence of priming agent
(TNF; 10 ng/ml), before addition of stimulus (50µl). Priming
with TNF-α induces degranulation with accompanying upregula-
tion of receptors that maximizes subsequent ROS release triggered
by chemoattractants (Bjorkman et al., 2008). When the FPR2
antagonist WRW4 was used, this compound was added 5 min
before stimulation with SAA and the NADPH-oxidase activity was
continuously recorded.
MEASUREMENT OF INTRACELLULAR Ca2+
Neutrophils (2× 107/ml) were labeled with Fura-2AM (2µM)
in calcium-free KRG with BSA (0.1%) at room temperature for
30 min and were from there on protected from light. For labo-
ratory procedure and details see reference (Karlsson et al., 2009)
The intracellular Ca2+ levels are plotted as the fluorescence ratio
(340/380 nm) over time.
NEUTROPHIL CULTURE
Purified neutrophils (5× 106/ml) were incubated (5% CO2, 37˚C)
for 20 min in complete medium [RPMI 1640 supplemented with
10% FCS and 1% penicillin/streptomycin (PEST)] or alternatively
in plasma (100%) from patients or controls. After addition of
rSAAh, rSAA1, or LPS at designated concentrations, the cells were
incubated for 20 h.
ASSESSMENT OF APOPTOSIS
Evaluation of cell death was performed essentially as described in
Christenson et al. (2012). In short, cells were stained with Annexin
V in combination with 7-AAD and analyzed by flow cytometry on
an Accuri C6 (Becton Dickinson, Mountain View, CA, USA). Data
were analyzed using CFlow plus software.
DETERMINATION OF L-SELECTIN EXPRESSION
The exposure of CD62L (L-selectin) on neutrophils was assessed
in a whole blood system (Bjorkman et al., 2010) by immunostain-
ing and FACS-analysis. All data were analyzed using WinMDI 2.8
software or CFlow Plus.
www.frontiersin.org April 2013 | Volume 4 | Article 92 | 3
Christenson et al. Native SAA lacks pro-inflammatory activity
QUANTIFICATION OF INTRACELLULAR IL-8, TOTAL IL-8 FROM CELL
CULTURE, AND CYTOKINES IN PLASMA SAMPLES
Freshly prepared neutrophils (106/sample) from patients
and controls were, after fixation and permeabilization (BD
Cytofix/Cytoperm Plus, BD, San Diego, CA, USA), labeled with
an allophycocyanin-conjugated anti-IL-8 Ab or an isotype con-
trol. Intracellular IL-8 was thereafter evaluated by flow cytometry
on the basis of allophycocyanin fluorescence using an Accuri C6
(BD, USA) and analyzed by CFlowPlus. For the quantification of
total IL-8 production after in vitro culture, Triton-X 100 (0.1%),
and the protease inhibitor Pefa-Bloc (1 mM) was added to cell cul-
tures and lysates were analyzed by a human IL-8 DuoSet ELISA
development kit (R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s description. Plasma (60µl, diluted 1:3)
from all patients were analyzed for IL-1β, IL6, IL-8, IL-10, IL-12,
GM-CSF, TNF, INF-γ, and IP-10 using a Bio-plex Pro Cytokine
assay (Bio-Rad Laboratories AB, Sundbyberg, Sweden) according
to the manufacturer’s instructions.
RESULTS
HUMAN SAA DOES NOT DRIVE PRODUCTION OF PRO-INFLAMMATORY
IL-8 IN PATIENTS WITH INFLAMMATORY ARTHRITIS OR OF KC IN A
MURINE MODEL WITH TRANSGENIC ADIPOSE TISSUE EXPRESSION OF
HUMAN SAA1
Recombinant hybrid SAA (rSAAh) potently induce the activation
of NF-κB in leukocytes, resulting in the production and release of
pro-inflammatory cytokines, e.g., IL-8 (He et al., 2008; Okamoto
et al., 2008). To study potential pro-inflammatory effects of native
SAA we enrolled nine patients with inflammatory arthritis and
circulating SAA levels varying between 3 and >400µM (Table 1).
Analyzing pro-inflammatory cytokines in the plasma from these
patients, we found the levels of IL-8 to be similar to that of healthy
FIGURE 2 | Elevated levels of SAA is not associated with heightened
expression of IL-8 in circulation of rheumatic patients, or of KC in a
mouse model of diet-induced obesity. (A) Cell-free plasma from nine
patients with inflammatory arthritis (P#1-#9; white bar) and three healthy
controls (black bar) were evaluated for IL-8 content using a Luminex
analysis; shown is mean (+SEM). (B) WT and transgenic mice expressing
human SAA1 in adipocytes were fed a high-fat diet to induce obesity.
Obese transgenic mice have circulating levels of human SAA1 similar to the
levels seen in human obesity. Plasma samples were analyzed by ELISA for
the murine IL-8 counterpart CXCL1/KC and are shown as mean (+SEM; WT
mice; n= 10 black bar, transgenic mice; n=8, white bar). Statistical
analyses were performed using unpaired t -tests (*p<0. 05; ns, not
significant).
controls (Figure 2A). For a number of other cytokines we found
that, although some were elevated in the patient group as a whole,
there was a remarkable lack of correlation between SAA concen-
trations and levels of inflammatory cytokines in patient plasma
(Figure 3).
Also in murine systems rSAAh has been shown to drive inflam-
matory signaling (Niemi et al., 2011). We next used an established
transgenic mouse model (Olsson et al., 2011) where human SAA1
is constitutively expressed in adipocytes. After the mice had been
challenged with a high-fat diet, circulating levels of human SAA1
were similar to the levels seen in human obesity (3.07± 0.91µM;
mean± SD, n= 8). The presence of human SAA1 in the trans-
genic mice did not seem to drive production of pro-inflammatory
cytokines, but instead plasma levels of the murine IL-8 homolog
KC were significantly lower in the transgenic mice than the WT
mice (Figure 2B).
Taken together, these data imply that native human SAA does
not drive the production of pro-inflammatory cytokines in cir-
culation, neither in inflammatory arthritis patients, nor in a
transgenic mouse model displaying moderately elevated levels of
human SAA1.
RECOMBINANT BUT NOT ENDOGENOUS SAA INDUCE NEUTROPHIL
IL-8 PRODUCTION
In order to study if circulating endogenous SAA induces
IL-8 production specifically in neutrophils, we analyzed freshly
prepared cells from patients and healthy controls by intracellular
immunostaining and flow cytometry. Patient neutrophils con-
tained detectable IL-8, however, the levels were not higher than
in neutrophils from healthy controls (Figure 4A). We next stud-
ied the effect of endogenous SAA on de novo synthesis of IL-8
by culturing purifird neutrophils for 20 h in vitro with or with-
out SAA-rich patient plasma (ranging from 15 to 428µM SAA;
Table 1) or complete medium with 10% FCS. The levels of IL-8
were equal between cells having experienced SAA-rich plasma and
cells incubated with control plasma (not shown). When spiking the
SAA-rich plasma or complete medium with 10µM of the rSAAh,
a significant and robust IL-8 production was observed, in the same
range as for SAA-rich plasma spiked with LPS (Figure 4B). The
addition of recombinant SAA1 (rSAA1) to SAA-rich plasma or
complete medium moderately increased IL-8 levels at this concen-
tration (Figure 4B). These data show that SAA-rich plasma do not
induce IL-8 production in neutrophils, while recombinant SAA
does. Further, the SAA-rich patient plasma does not appear to con-
tain factors that neutralize responses to recombinant SAA. Hence,
the recombinant SAA proteins are functionally different from the
endogenous protein in circulation of patients with inflammatory
arthritis.
RECOMBINANT BUT NOT ENDOGENOUS SAA SHED NEUTROPHIL
L-SELECTIN
To further explore potential neutrophil activating properties of
endogenous SAA, we monitored L-selectin expression. This adhe-
sion molecule is present on resting cells, but is rapidly cleaved
off from the cell surface during cell activation (Ley et al., 2007).
Whole blood samples from healthy controls were stimulated with
the recombinant forms of SAA for 20 min after which the surface
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FIGURE 3 | High SAA levels in blood do not correspond to increased
levels of inflammatory cytokines. Plasma levels of inflammatory cytokines
in the individual patients included in the study. Dotted lines represent the
detection limits for each cytokine; samples lower than detection limit were
given a value of 0.1 pg/ml to facilitate presentation of data. Circulating SAA
levels for each patient are shown (additional data inTable 1).
expression of L-selectin was measured by flow cytometry. TNF was
used as a positive control, inducing an activated neutrophil phe-
notype devoid of surface L-selectin (Figure 5). Both recombinant
forms of SAA-induced L-selectin shedding in a dose-dependent
manner (Figure 5A). The rSAAh was more potent than rSAA1,
with an EC50 value 100-fold lower, but at 20µM both recombi-
nant forms of SAA significantly induced shedding of L-selectin
(Figure 5A). In contrast, circulating neutrophils from patients
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FIGURE 4 | Recombinant, but not endogenous, SAA induces IL-8
production in human neutrophils. (A) Freshly prepared neutrophils
were analyzed for intracellular IL-8 content using flow cytometry. The
figures show representative histograms (P#7, left panel) and averages
(+SEM) of the mean fluorescence intensity from three controls (black
bar) and P#4-7 (white bar). (B) Freshly prepared patient neutrophils
(P#1, #2, #3, #5, and #6) were incubated for 20 h in 100%
endogenous plasma (left) or complete medium; RPMI+10% FCS and
1% PEST (right) with or without addition of rSAA1 (10µM), rSAAh
(10µM), or LPS (100 ng/ml). Total IL-8 content in the cultures was
measured by ELISA and is shown as mean (+SEM). Statistical
analyses were performed using unpaired students t -test (A) and
One-way ANOVA followed by Dunnett‘s multiple comparison test (B).
??p<0.01; ns= not significant.
with endogenous SAA levels far exceeding 20µM displayed intact
levels of surface L-selectin, shown in Figure 5B by a representative
example (patient #9 with 197µM SAA in plasma). This confirms
our earlier report (Bjorkman et al., 2010) and we conclude that
SAA-rich plasma from patients with rheumatic disease fails to
activate neutrophils in contrast to the recombinant forms of SAA
which both induce L-selectin shedding.
THE RECOMBINANT SAA VARIANTS DIFFER IN POTENCY REGARDING
NEUTROPHIL ACTIVATION
Our results so far indicated that the two recombinant forms of SAA
differ in potency regarding the induction of IL-8 production and
L-selectin shedding, despite being very similar on the amino acid
level. We investigated whether a similar pattern was evident also for
other features of neutrophil activation. We have previously shown
that the rSAAh dose-dependently delays neutrophil apoptosis at
nanomolar concentrations (Christenson et al., 2008) and activates
the NADPH-oxidase to produce reactive oxygen species (ROS) at
higher doses (Bjorkman et al., 2008). For rSAA1 we also found a
delayed neutrophil apoptosis, although with a potency that was
approximately 100-fold lower than that of rSAAh (Figure 6A).
A similar picture was evident for ROS production. Using TNF
primed cells (in order to maximize responses to weak agonists),
the highest tested concentration of rSAA1 (10µM) resulted in
low, but clearly measurable, levels of ROS release (Figure 6B). As
compared to rSAAh, the potency for induction of ROS production
was again approximately 100-fold lower (Figure 6B) Experimental
limitations prohibited us from investigating rSAA1 at higher con-
centrations. We conclude that although rSAAh and rSAA1 induce
activation of the same features in human neutrophils, the hybrid
form is around 100-fold more potent than rSAA1.
RECOMBINANT SAA1 ACTIVATES FPR2 ON PRIMARY NEUTROPHILS
A wide variety of receptors have been claimed to recognize
SAA, and among those is FPR2 (formerly known as formyl pep-
tide receptor-like 1, FPRL1), a chemotactic receptor present on
human phagocytes (Fu et al., 2006). We have previously demon-
strated that even though FPR2 is capable of recognizing rSAAh
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FIGURE 5 | Recombinant, but not endogenous, SAA activates
neutrophils to shed L-selectin. (A) Whole blood from healthy donors was
stimulated in vitro as indicated for 20 min and surface expression of L-selectin
was monitored by flow cytometry after gating on neutrophils on the basis of
forward and side scatter. Stimulation with rSAAh (open squares) or rSAA1
(closed squares) induced L-selectin shedding in a dose-dependent manner.
Data are shown as mean (±SEM, n=3–6) and statistical analysis was
performed using One-way ANOVA followed by Dunnett‘s multiple comparison
test where the SAA-treated samples were compared to the unstimulated
control (??p<0.01; ???p< 0.001). Stimulation with the positive control TNF
(10 ng/ml; closed triangle) is shown for comparison. (B) Freshly drawn blood
from P#9 (gray; 197µM SAA in plasma) and one healthy control (black) were
analyzed for L-selectin expression after treatment with (closed histograms) or
without (open histograms) TNF-α (10 ng/ml). Histograms are representatives
of numerous patients assayed independently, consistently showing resting
levels of L-selectin that was efficiently shed by treatment with TNF.
in receptor-transfected cell lines, this receptor is not responsible
for mediating rSAAh-induced ROS production in human neu-
trophils (Bjorkman et al., 2008). We utilized the FPR2-specific
antagonist WRW4, at a concentration (5× 10−6 M) where it does
not interfere with signaling from other chemoattractant receptors
(data not shown) and (Stenfeldt et al., 2007), and confirmed that
ROS production induced by rSAAh is not mediated through FPR2
(Figure 7A). In contrast, the ROS production evoked by rSAA1
was completely inhibited by the FPR2 antagonist, indicating that
FPR2 mediates the rSAA1-induced ROS release (Figure 7A). Nei-
ther rSAAh-, nor rSAA1-induced ROS production was inhibited
by the specific FPR1 antagonist cyclosporin H (not shown).
The signal transduction from chemoattractant receptors to
the NADPH-oxidase most often involves transient elevations of
cytosolic Ca2+. Stimulation of primary neutrophils with either
of the two recombinant SAA variants resulted in clear cytosolic
Ca2+ transients (Figure 7B). In complete agreement with the ROS
production data (Figure 7A), the FPR2 antagonist WRW4 com-
pletely abrogated the Ca2+ signal induced by rSAA1, whereas the
signal induced by rSAAh was insensitive to the FPR2 antagonist
(Figure 7B). Thus, rSAA1 is indeed a bona fide ligand for FPR2 in
human neutrophils. Further, the relatively minor amino acid dif-
ferences between rSAA1 and rSAAh result in a marked difference
in receptor usage, where the receptor utilized by rSAAh remains
unidentified.
DISCUSSION
The systemic acute phase response to inflammation results in dra-
matic changes in the serum levels of acute phase proteins. These
proteins are mainly produced by the liver and are part of an
evolutionarily conserved system aimed at controlling infections,
eliminating components from damaged tissue, and to protect
against inflammation-evoked (collateral) damage. The protein
SAA is one of the most notable acute phase reactants and it has
been estimated that 2.5–3% of total liver protein synthesis is ded-
icated for SAA production during acute inflammation (Kisilevsky
and Manley, 2012). The concentrations of SAA in circulation may
within hours increase 1000-fold during an acute phase response,
but may also be chronically elevated in individuals with various
inflammatory conditions, including atherosclerosis, obesity and
not least rheumatologic diseases (Cunnane et al., 2000). Such
sustained high levels of SAA may lead to reactive amyloidosis,
a pathological condition characterized by extracellular deposits of
SAA in amyloid fibrils that gradually leads to progressive organ
failure (Benson et al., 2006). The exact mechanism for how SAA
is transferred into an amyloidogenic, i.e., aggregated form, in
humans is not known, though several mechanisms have been sug-
gested (Raynes and McAdam, 1991; Ajiro et al., 2006; Noborn et al.,
2012).
Aside from the involvement in reactive amyloidosis, the physio-
logical and pathological roles of SAA are somewhat unclear. Early
reports seem to favor anti-inflammatory properties of SAA (Ben-
son and Aldo-Benson, 1979, 1982) in line with a general role of
acute phase reactants in dampening the inflammatory onslaught
that triggers their synthesis. This view rapidly changed by the
advent of the rSAAh that in 1994 was shown to function as a
chemoattractant for primary human monocytes and neutrophils
(Badolato et al., 1994). A few years later the receptor specificity
for SAA was determined by showing that an FPR2-transfected cell
line displayed chemotactic migration toward rSAAh, identifying
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FIGURE 6 |The recombinant SAA proteins activate neutrophils
with different potency. (A) Neutrophils purified from buffy coats
were incubated for 20 h with addition of medium, or rSAA1 (filled
squares; n=3) at the indicated concentrations. Apoptosis was
thereafter evaluated by flow cytometry on the basis of Annexin V
positive events. Shown for rSAA1 is mean (±SEM) and one
representative experiment with rSAAh (open squares) is shown for
comparison. Statistical analysis was performed using repeated
measurement ANOVA followed by Dunnett‘s multiple comparison
test (??p<0.01). (B) Extracellular release of ROS from TNF-α primed
neutrophils after addition (arrow) of indicated concentrations of rSAA1
or rSAAh. Representative curves (upper) are shown with arrows
indicating the addition of SAA, as well as mean peak values (±SEM;
lower) from three independent experiments.
rSAAh as the first endogenous ligand for FPR2 (Su et al., 1999).
Since then, most work on the effects of SAA on inflammatory
cells has been performed with rSAAh and found it to possess a
wide variety of pro-inflammatory activities including the capac-
ity to induce IL-8 production (Furlaneto and Campa, 2000; He
et al., 2003; Christenson et al., 2008). Investigations using endoge-
nous, native SAA are considerably scarcer. We have earlier shown
that SAA-containing fractions, derived from hydrophobic inter-
action chromatography followed by gel filtration, were able to
suppress neutrophil apoptosis (Christenson et al., 2008). On the
other hand, another SAA preparation that was>98% pure did not
affect cytokine production (Bjorkman et al., 2010) or neutrophil
apoptosis (unpublished data). These somewhat incongruent data
indicate that the purification of SAA from human plasma is by no
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FIGURE 7 | FPR2 mediates ROS production and Ca2+ signaling induced
by rSAA1, but not by rSAAh. (A) The ROS release from TNF primed
neutrophils was evaluated with a chemiluminescence assay after addition
of rSAAh or rSAA1 (10µM). When applicable, the FPR2-specific antagonist
WRW4 (5×10−6 M) was added 5 min prior to stimulation. The bars show
percent of control (no inhibitor) as mean (+SEM; n=4) (B) Fura-2 labeled
neutrophils were stimulated (arrows) with rSAAh (10µM; left) or rSAA1
(10µM; right) in the presence or absence of the FPR2-specific antagonist
WRW4 (5×10−6 M). Traces depict intracellular Ca2+ levels plotted as the
fluorescence ratio (340/380 nm) over time. The traces are representatives
out of three to six independent experiments.
means a trivial task and that low contaminating levels of, e.g., other
lipoproteins, are likely to complicate interpretation of data. In vivo,
pure SAA would be a rare occurrence and we therefore believe that
experiments carried out with natural, non-purified, material such
as SAA-rich plasma are crucial to obtain a true picture of how this
protein really functions.
One recent study of melanoma patients has argued that endoge-
nous SAA drives the production of IL-8 (as well as IL-10) in cir-
culating neutrophils (De Santo et al., 2010), and if extrapolated to
other inflammatory conditions, this finding should mean that cells
derived from other patient groups associated with elevated SAA
levels should also display increased IL-8 content. We found no such
IL-8 increase in circulation or in neutrophils from inflammatory
arthritis patients,but instead there was a notable lack of correlation
between SAA levels and circulating levels of inflammatory
cytokines in our group of patients (Table 1; Figure 3). These nine
patients represent a limited group and the patients were not sub-
jected to the study in terms of a specific diagnosis but rather the
fact that they had elevated levels of SAA. In combination with data
from the mouse model where the transgenic mice were actually
found to express less KC compared to WT mice, we find it clear that
SAA does not drive the production of pro-inflammatory cytokines.
Thus, the elevated levels of IL-8 reported in neutrophils from
melanoma patients, must be explained by a factor other than SAA.
As mentioned, a number and variety of neutrophil receptors
have been suggested to recognize rSAAh. The typical activation
pattern induced by rSAAh, involving transient Ca2+ elevation and
ROS production, suggests that a chemoattractant receptor is at
least partly responsible for its cellular effects. The FPR2 is one
such chemoattractant receptor that has been demonstrated to rec-
ognize rSAAh (Su et al., 1999; He et al., 2003; Lee et al., 2006).
We have earlier shown that rSAAh can activate cells through FPR2
when the receptor is over-expressed on cell lines, while this par-
ticular receptor is not used for activation of the ROS-producing
NADPH-oxidase in primary human neutrophils (Bjorkman et al.,
2008). Our data described herein support this, but also show that
the other recombinant SAA, rSAA1, indeed activates FPR2 on
primary human neutrophils. Further proof that the two recombi-
nant SAA proteins activate neutrophils via different receptors can
be obtained from desensitization experiments (Bjorkman et al.,
2008). Neutrophils desensitized with a high affinity ligand for
FPR2, WKYMVm, were still able to respond to rSAAh while the
rSAA1 response was clearly reduced (data not shown). It should be
noted that we also observed FPR2-independent effects of rSAA1;
WRW4 did not significantly attenuate the anti-apoptotic effect of
rSAA1 (data not shown).
It is clear that the relatively minor alterations to the amino acid
sequence of rSAA1 into rSAAh, changes the receptor preference
of the proteins. Such shifts in receptor usage after small variations
in the primary sequences are well known for FPR family receptor
ligands (Fu et al., 2006). Furthermore, moderate changes in SAA
sequence have been shown to significantly alter fibril formation
capacity (de Beer et al., 1993). With this in mind, it is vital for
recombinant proteins to share the sequence of the original pro-
tein in order for biologically meaningful conclusions to be drawn.
Hence, rSAA1 should be a better substitute for endogenous SAA
since its sequence is identical to human SAA1 (with the excep-
tion of the N-terminal methionine, presumably added in order to
initiate transcription in the bacterial expression system).
It has recently been debated in Arthritis & Rheumatism (van
den Brand et al., 2013) whether the use of recombinant mole-
cules is valid for studying the relationship between SAA and joint
destruction in inflammatory arthritis (Connolly et al., 2012). In
line with the findings by van den Brand et al. (2013), also our
data indicate that rSAAh is more potent than rSAA1 in vitro.
More importantly, our findings (this paper and Bjorkman et al.,
2010) demonstrate a fundamental difference in terms of function
between the recombinant and endogenous SAAs. The underlying
reason for this dissimilarity is yet unknown, but one hypothesis
would be a difference in the association to lipids. The SAA pro-
teins are typically associated with high-density lipoprotein (HDL)
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and such association could potentially abrogate pro-inflammatory
activity of endogenous SAA (Magy et al., 2007). It was recently
suggested that only lipid-poor SAA (and not HDL-associated)
stimulates cytokine production (Kim et al., 2012), and apart from
insoluble amyloid aggregates the existence of lipid-free SAA is
highly unlikely (Kisilevsky and Manley, 2012). The difference in
neutrophil activating potential between endogenous and recom-
binant SAA could then be explained by a lack of HDL association
by the recombinant proteins. However, in our hands (Bjorkman
et al., 2010; and this study) recombinant SAA variants maintained
activity after incubation in human plasma (healthy or inflam-
matory), which is a rich source of HDL and other lipids. Since
the N-terminal part of SAA is known to determine lipid bind-
ing (Patel et al., 1996), one possible determining factor is that
the N-terminal methionine needed for bacterial synthesis of the
recombinant proteins alters HDL association.
Our results showing that endogenous SAA lacks the pro-
inflammatory effects that are seen for the recombinant vari-
ants are in many ways similar to the controversy regarding a
potential pro-inflammatory effect of C-reactive protein (CRP).
Whereas recombinant CRP activates a wide variety of immune
cells, evidence of pro-inflammatory activity in the endogenous
protein is lacking (reviewed in Ray et al., 2006). It has been shown
that recombinant CRP in fact is heavily contaminated by bacterial
endotoxin (Pepys et al., 2005) and we cannot completely rule out
that contaminating bacterial products contribute to certain effects
of the recombinant SAAs (e.g., delay of apoptosis). However,
the Ca2+ transients and ROS release triggered by the recombi-
nant SAAs are functional features that are certainly not induced
by LPS.
We conclude that even though recombinant SAAs can be valu-
able tools for studying various aspects of neutrophil activation,
they are not valid substitutes for mimicking the role of endogenous
SAA during an acute phase response.
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